Saturday, December 8 - Scientific Presentations

OncoLink Booth 264 at ASH 2001.

Analysis of Predisposing Factors for Hepatic Veno-Occlusive Disease after Treatment with Gemtuzumab Ozogamicin (Mylotargr, CMA-676). Presenter: Edward Stadtmauer University of Pennsylvania Cancer Center Background: Hepatic veno-occlusive disease (VOD) occurs frequently after hematopoietic stem cell transplantation (HSCT) but is rarely seen with other forms of therapy. ...
Candidate Gene Targets of the c-Myb Protooncogene in Human Myloid Leukemia Presenter: Susan E. Shetzline Institution: University of Pennsylvania Background: The c-Myb proto-oncogene encoded transcription factor, Myb is required for normal and malignant hematopoeisis. Ectopic c-Myb expression can transform...
Inter-Institutional Second Opinion Pathologic Review of Lymphoproliferative Disorders After WHO Classification. Presenter: Jonathon Silberstein Affiliation: Memorial Sloan-Kettering Cancer Center Background: The World Health Organization (WHO) classification of lymphoproliferative disorders is the most recent classification scheme available. It...
Low Penetration of Imatinib (STI571) into the CSF Indicates the Need for Standard CSF Prophylaxis in Patients with CML Lymphoid Blast Crisis and Philadelphia Chromosome Positive ALL Presenter: Jose F. Leis Affiliation: Oregon Health & Sciences University Background: Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ ALL) are hematologic malignancies caused by the...
Novel Erythropoeisis Stimulating Protein (Aranesp) Enhances Pegylated Soluble Tumor Necrosis Factor Receptor Type 1 (PEG sTNF-R1) Alleviation of Anemia of Chronic Disease (ACD) in a Rodent Model of Systemic Inflammation. Presenter: Greg Stoney Affiliation: Amgen Inc. Introduction Anemia of Chronic Disease is commonly associated with several chronic inflammatory disease states. ACD has a multifactorial pathogenesis mediated by multiple inflammatory...
Positron Emission Tomography with 18F-FDG in the Evaluation of Post-Treatment Residual Mass in Patients with Malignant Lymphoma. Presenter: Ralph Naumann Affiliation: University Hospital, Dresden, Germany Background: Management of residual mass after lymphoma treatment is a problematic issue for oncologists. It is not easy to determine if such masses represent active...
STI-571 in the Treatment of Children with Philadelphia (Ph+) Chromosome-Positive Leukemia: Results from a Children's Oncology Group (COG) Phase I Study. Presenter: Martin A. Champagne Background: STI-571 is a novel chemotherapeutic agent that selectively inhibits the abnormal tyrosine kinase that results from the translocation of the c-abl gene on chromosome 9 to one of two breakpoint regions...
Study of Bone Marrow Involvement in 1161 Consecutive Hodgkin's Lymphoma Patients. Presenter: Alessandro Lewis Affiliation: Piemonte Hodgkin's Disease Registry. Alessandria, Italy Background In Hodgkin's Disease(HD) bone marrow involvement(BMI) has been reported as a unfavorable prognostic factor. Accordingly, bone marrow...
Utility of 18-FDG-PET Scanning in Lymphoma by WHO Classification Presenter: Rebecca L. Elstrom Background: 18-FDG-PET scanning is an important imaging modality in the staging and monitoring of many malignancies, including lymphoma. Some tumors, however, do not have the high glucose uptake needed for 18-FDG...